Skip to main content
Download PDF

The intervention strategies and service model for pharmacist-led diabetes management: a scoping review

BMC Health Services Research volume 23, Article number: 46 (2023) Cite this article

Abstract

Background

There is increasing intervention activities provided during pharmacist-led diabetes management. Nevertheless, there is an unclear definition of the activities involved during the intervention. Thus, this study aimed to describe the type of intervention strategies and service model provided during pharmacist-led type 2 diabetes management and service outcomes.

Methods

This study utilized the scoping review methodology of the Joanna Briggs Institute Reviewers’ Manual 2015. Articles on pharmacist-led diabetes management focusing on the service content, delivery methods, settings, frequency of appointments, collaborative work with other healthcare providers, and reported outcomes were searched and identified from four electronic databases: Ovid Medline, PubMed, Scopus, and Web of Science from 1990 to October 2020. Relevant medical subject headings and keywords, such as “diabetes,” “medication adherence,” “blood glucose,” “HbA1c,” and “pharmacist,” were used to identify published articles.

Results

The systematic search retrieved 4,370 articles, of which 61 articles met the inclusion criteria. The types of intervention strategies and delivery methods were identified from the studies based on the description of activities reported in the articles and were tabulated in a summary table.

Conclusion

There were variations in the descriptions of intervention strategies, which could be classified into diabetes education, medication review, drug consultation/counseling, clinical intervention, lifestyle adjustment, self-care, peer support, and behavioral intervention. In addition, most studies used a combination of two or more intervention strategy categories when providing services, with no specific pattern between the service model and patient outcomes.

Peer Review reports

Background

The prevalence of diabetes is increasing worldwide [1]. The prevalence of diabetes in the developed and developing countries is expected to increase by 42% and 170%, respectively, by 2030 [2]. This is particularly a concern in developing countries, as they are commonly affected by rapid population growth, an aging community, unhealthy local diet, urbanization, obesity, unhealthy lifestyle, and poor access to quality health care [3]. As these problems arise, the cost of managing the illness increases. The economic burden of diabetes has necessitated the development of effective interventions that simplify early diagnosis, promote effective care, and enhance primary prevention [4].

The management of diabetes includes maintaining a healthy lifestyle, such as meal planning, physical activity, and medication adherence. Since healthcare providers are not always present, developing self-management skills is critical for diabetes management. Patient education programs have been implemented to educate patients on their active roles in disease management. These programs were reported to result in a better understanding of patients’ perspectives and attitudes toward health, as well as their compliance with drug decisions, risk factors, and overall quality of life [5]. Although pharmacotherapy is an effective treatment modality to achieve optimal glycemic control and prevent the development of diabetes complications, its efficacy is often limited by poor medication adherence among patients with diabetes. Approximately 43.4% of diabetic patients in low- and middle-income countries do not adhere to their pharmacotherapy treatments [6].

An increasing number and types of intervention strategies are being developed to complement pharmacotherapy in diabetes management. Intervention strategies that aim to promote better disease control include patient-mediated strategies through interactions with patients or via the information provided by or to patients [7]. The types of intervention strategies reported in previous studies include counseling, psychological and social interventions, patient empowerment, patient-centered training, explanation of possible adverse events, nutritional therapy, physical activity, and health coaching [8]. Intervention strategies are introduced based on the capacity and needs at the local level and are provided in combination or as single strategies. In addition, patient-centered services facilitated by multiple healthcare professionals, including pharmacists, have shown to enhance outcomes [9,10,11].

Pharmacists who are knowledgeable in pharmacotherapy are well-trained in identifying patients’ pharmaceutical care issues, such as adverse drug reactions and non-adherence. In addition, pharmacists who are working in outpatient and ambulatory care who are more accessible to the community, are well-positioned to educate, monitor, and support medication adherence and self-care of diabetic patients, which may contribute to the achievement of therapeutic success in diabetes management. An example of a pharmacist-led diabetes management service includes a review of medicines that aim to improve patients’ understanding of the disease and increase their adherence to treatment. Several systematic evaluations have been undertaken throughout the years to investigate the impact of pharmacist-led diabetic care [12,13,14]. Nonetheless, the studies’ primary focus was on the treatments’ impacts and results, with just a brief mention of the particular tactics and service models delivered. Exploring the specifics of the intervention’s activities and strategies may provide insight into similarities and differences that may or may not have an impact on patient outcomes.

A systematic review by Presley et al. (2018) on interventions to improve medication adherence among adults demonstrated the role of pharmacists in improving diabetes control [8]. In their study, the intervention by pharmacists enhanced diabetes outcomes (standardized mean difference, -0.68; 95% confidence interval, -0.79, -0.58; p < 0.001) with subgroup analysis by intervention strategy, and the type of intervention and outcome measures produced similar results. In their study, nevertheless, the intervention strategies were classified as educational, behavioral, or a combination of both, with an unclear definition of the activities involved. Since many different activities were reported to be provided during pharmacist-led diabetes management services, it is worth exploring and classifying intervention strategies based on their specific activities [8]. In addition, the effectiveness of these two broad intervention strategies was inconsistent between studies in which the best interventions to improve nonadherence could not be determined [8]. Thus, this study aimed to provide a review of the type of individualized intervention strategies and service model provided during pharmacist-led type 2 diabetes management, which includes reviewing specific service content, such as information on the activities involved, delivery methods, settings, frequencies of appointments, and collaborative work with other healthcare providers and their outcomes.

Methods

As the study aimed at providing an overview of the intervention strategies and service model provided during pharmacist-led type 2 diabetes management, scoping review methodology was deemed the most appropriate method to be applied. The current study utilized the scoping review methodology of the Joanna Briggs Institute Reviewers’ Manual 2015 [15]. The manual was one of the latest published on scoping reviews methodology. The step-by-step approach in the manual was well described and provided clear guidance for conducting a scoping review. Articles on pharmacist-led diabetes management focusing on service content, delivery methods, settings, frequencies of appointments, collaborative work with other healthcare providers, and reported outcomes were searched and identified.

Search criteria

Articles were searched from four electronic databases: Ovid Medline, PubMed, Scopus, and Web of Science from 1990 to October 2020. Relevant Medical Subject Headings (MeSH) and keywords such as “diabetes,” “medication adherence,” “blood glucose,” “HbA1c,” and “pharmacist” were used to identify published articles. The specific search strings used for the search can be found in the supplementary material. To increase the specificity and sensitivity of the identified articles, MeSH terms and keywords were combined using the Boolean operator, AND or OR, where appropriate. The reference lists of the retrieved papers were screened for potentially relevant papers that were missing during the electronic search.

Study selection

All retrieved articles were imported to Mendeley, a reference management system software, and duplicates were removed. Articles were included if they had been conducted as a randomized controlled trial; intervention conducted by pharmacists aimed at improving medication adherence and/or glycemic control, including diabetic patients aged 18 and above; and conducted in outpatient or ambulatory settings and reported glycemic control or medication adherence level as the outcomes. Multicomponent team-based care and programs were included if the study defined the program as a pharmacist-led program and the involvement of other healthcare providers are only to address specific issues such as prescribing and meal planning. Only studies with randomized controlled trials (RCTs) study design were included as they usually represent optimal study design and regarded as highest quality evidence. RCTs usually minimize bias in their study procedure and combining RCTs with other study designs may increase study’s heterogeneity, hence, making comparison and conclusion difficult to be made. In addition, randomized controlled trials report usually includes a more detailed information on their intervention programs making it possible for relevant and accurate details to be extracted. Articles were excluded if they had been conducted in a well-controlled environment, such as in a university or academic institution that did not reflect a real practice setting; full articles could not be retrieved; and were not published in the English language.

Articles were initially screened by F.H. based on their title and abstract. The exclusion process using titles or abstracts by F.H. occurred only if the reason for exclusion was clear. If there was uncertainty, the article was not excluded, and each member of the research team (F.H., E.H., A.M.A., C.W.W.) reviewed the article. All excluded “full text” articles were independently reviewed by F.H., E.H., A.M.A., and C.W.W. to ensure the validity of the process. Any disagreements regarding whether a study should be included or excluded were resolved through consensus when the majority indicated their agreement over the matter.

Data extraction

F.H. performed data extraction for all articles, which was checked by E.H. Extracted data included title, year of publication, authors and location of the study, contents of the intervention, delivery approaches, healthcare workers involved, frequency of appointments, follow-up period, and reported outcomes. C.W.W. and A.M.A. reviewed the extracted data in a table form. Discrepancies were discussed and resolved by consensus.

Data analysis

Data analysis was conducted through a narrative synthesis of the articles by evaluating and comparing the pharmacist-led interventions reported in the articles. The results were summarized according to the type of service content, delivery methods and settings, frequency of appointments, collaborative work with other healthcare providers, and outcomes of glycemic control and medication adherence. The types of service content and delivery methods with their definitions were identified from the studies based on the description of activities reported in the articles and are tabulated in the summary table. The code was initially categorized by F.H. and refined by E.H. The final coding was assessed by all team members, F.H., E.H., A.M.A., and C.W.W., and disagreement was resolved through consensus. The current study reported that the glucose control outcome as significant if at least one of the result of the glucose readings measured by the studies (random blood glucose, fasting blood glucose, HbA1c or post-prandial blood glucose) was reported significant.

Results

The systematic search retrieved 4,370 articles located through the electronic database search. After removing duplicates and titles/abstracts that were unrelated to pharmacist-led diabetes management, 140 articles were included in the full-text review. After applying the inclusion and exclusion criteria, 61 articles were included in the analysis. Figure 1 summarizes the PRISMA flow process for the identification, screening, and inclusion of the identified articles.

Fig. 1
figure 1

Flow chart of the search result

Full size image

All included studies were randomized controlled trials. Studies included were from Australia (n = 2), South America (n = 4), North America (n = 16), Europe (n = 7), Asia (n = 27), and Africa (n = 2). The earliest study was published in 1996, and most studies (n = 48) were published after 2010. Pharmacist interventions on diabetes management were provided in settings, such as community health centers (n = 4), community pharmacies (n = 11), outpatient clinics (n = 44), and outpatient pharmacies (n = 2). Table 1 summarizes the characteristics of the included studies.

Table 1 Summary of studies and description of service model and intervention provided
Full size table

Most interventions were conducted by multidisciplinary teams of healthcare providers, including pharmacists, doctors, nurses, dietitians, and diabetes educators (n = 37). Only 24 of the included studies contained interventions performed solely by pharmacists. In such settings, the interventions conducted by pharmacists, which are rarely clinical interventions, include diabetes education, medication review, drug counselling, self-care recommendations, and lifestyle adjustments.

The method of service delivery included face-to-face sessions with individual patients, which was the most common method used (n = 51), scheduled telephone calls (n = 27), group sessions (n = 8), and visits to patients’ homes (n = 2). Fifteen studies used face-to-face meetings as the single method to deliver interventions [16,17,18,19,20,21,22,23,24,25,26,27,28,29,30]. Another four studies utilized single delivery group sessions [31,32,33] and phone calls [34] to deliver interventions. Three studies used a combination of three intervention delivery methods [35,36,37]. The most common combination of delivery methods was face to face meeting and phone calls (n = 22) [35, 37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56]. During the interventions, several delivery aids were used, such as videos (n = 2), printed materials consisting of a summary of important information for patients (n = 20), email reminders (n = 1), patient diaries (n = 11), and pillboxes (n = 6).

Eight intervention strategy categories were identified in the included studies. Table 2 provides a detailed description of the categories and potential activities involved. Intervention strategies were categorized into diabetes education, medication review, drug consultation/counseling, clinical intervention, lifestyle adjustment, self-care, peer support, and behavioral intervention. The most popular strategy for this was diabetes education. The educational components of these interventions primarily aimed to increase the patients’ general understanding of their condition by discussing the expected degree of diabetic control, risk of complications, and ways to minimize these risks [57]. Patients were also informed about the types of medications used to treat their disease [58].

Table 2 Description of intervention categorization and potential activities involved
Full size table

Only seven studies utilized a single intervention strategy, which included diabetes education [17, 35, 59, 60], medication review [37], and drug consultation/counseling [61, 62]. Most studies incorporated two or more intervention strategy categories. In particular, 17 combined two strategies [16, 28, 33, 34, 36, 39, 41, 45, 48, 55, 63,64,65,66], 18 combined three [18, 19, 23, 24, 26, 30, 38, 44, 46, 50, 51, 53, 54, 67,68,69,70,71], 16 combined four [20, 22, 25, 27, 29, 32, 37, 42, 43, 47, 49, 52, 56, 72,73,74], 2 combined five [75, 76], and 1 combined six [31]. The most commonly utilized intervention strategy was diabetes education (n = 49), whereas the least utilized service content category was peer support (n = 1).

The follow-up periods of the pharmacists’ interventions differed in each study and ranged between 1.5 [67] and 24 months [42]. One study followed up patient for 2 months [59], nine for 3 months [16, 52, 53, 56, 60, 61, 64, 70, 74], five for 4 months [21, 25, 31, 45, 68], three for 5 months [23, 50, 53], fourteen for 6 months [22, 27, 30, 36, 39, 40, 44, 46, 49, 62, 73, 75], three for 8 months [18, 55, 72], four for 9 months [29, 33, 37, 41], eighteen for 12 months [20, 24, 26, 28, 35, 38, 43, 47, 48, 51, 54, 63, 65, 66, 69, 71, 76, 77], one for 13 months [32] and another one for 16 months [10]. The most common follow-up period for the interventions was 12 months (n = 19, 31.1%), and the mean intervention duration was 7.8 months.

The frequency of follow-up varied from a minimum of a single follow-up [21, 28, 61, 69] to 24 follow-ups [42]. Five studies set a frequency of two follow-ups [44, 48, 59, 62, 68], twelve set three follow-ups [16, 20, 22, 29, 49, 52, 60, 64, 65, 70, 72, 74], five set four follow-ups [17, 18, 24, 31, 45], two set five follow-ups [53, 76], eleven set six follow-ups [19, 26, 27, 30, 33, 36, 39, 54, 67, 75, 77], four set eight follow-ups [10, 32, 37, 38], another four set nine follow-ups [40, 46, 66, 73], one set ten follow-ups [25], and six set twelve follow-ups [35, 43, 51, 56, 63, 71]. Five of the studies did not describe the number of follow-ups carried out in detail [23, 41, 47, 50, 55]. The mean number of follow-ups that the patients received was six. The most common number of follow-ups reported by the studies was three (n = 13, 21.43%).

Most studies (n = 36) reported glucose control as the outcome, 24 reported glucose control and medication adherence as the outcomes, and one study reported medication adherence as the outcome. Most studies (n = 41) also showed significant improvement in glucose control, which was measured by glycosylated hemoglobin, fasting or random blood glucose levels, or a combination of these. Meanwhile, 22 of the 25 studies reported significant improvement in medication adherence measured using the eight-item Morisky Scale, Malaysian Medication Adherence Scale, pill-count, self-reported adherence scale, dispensing history, diagnostic adherence to medication scale, or Morisky Green Levine Medication Adherence Scale.

Discussion

The current scoping review aimed to evaluate the type of interventions and service model provided during the provision of pharmacist-led type 2 diabetes management which previously had unclear classification with no detail on the activities involved. This includes a review of the type of service content, delivery methods, settings, frequencies of appointments, collaborative work with other healthcare providers, and reported outcomes. Pharmacist-led diabetes interventions were provided in six continents, with most studies (n = 37) conducted in Asia. This was not surprising since the highest prevalence of diabetes is found in Asian countries [1]. Thirty of the studies were conducted in high-income countries, one in low-income country, 13 in lower-middle-income countries, and 17 in upper-middle-income countries. There is a lack of interest in the topic in low-income countries even though the prevalence of non-adherence towards treatment is high and the promotion of effective treatment plan would help reduce the burden of diabetes management in such countries [4, 6]. Most services (n = 37) were provided by a multidisciplinary health care team, and only a few (n = 24) were conducted solely by pharmacists. Nevertheless, in these studies, most showed that pharmacists also worked directly with a physician on patient issues, for example, if the patient required approval for prescription adjustment and specific diet plan such as fasting. A meta-analysis study on the multidisciplinary team approach to coordinated pharmaceutical care found that such collaborations reduced the likelihood of patients’ hospitalization and increased their quality of life [78].

Face-to-face sessions were the most common method for pharmacist-led diabetes management reported in the included studies. This traditional method of service delivery is well established and generally well accepted by patients. Most studies reported good patient retention throughout the study period. However, unlike in a trial environment, patients in a real-world setting may not be able to complete proper follow-ups with frequent face-to-face appointments. In clinical trials, patients are routinely reminded to attend their subsequent appointments and are often rewarded with tokens for their participation in the trials. Therefore, they might have different motivations for retaining themselves in the program compared to actual patients outside clinical trial settings. For example, in a diabetes prevention program in England involving 100,000 patients, only 22% of the participants completed the program [79]. Therefore, it is important to review an intervention program beyond the “controlled” environment and ensure its convenience for the patient. Providing more interventions through phone calls and video conferences should be explored in the future, as they are generally equally effective as face-to-face sessions [80]. Home visits may suit patients with logistics issues who require frequent clinic visits. Meanwhile, group sessions may be useful for behavioral interventions that include peer support and mentoring activities [81].

Eight categories of pharmacist-led service contents were identified from the reported studies, which included diabetes education, medication review, drug consultation/counseling, clinical intervention, lifestyle adjustment, self-care, peer support, and behavioral intervention. The majority of the studies combined two or more service content categories for intervention. Although the best combination of interventions for diabetes management could not be determined due to an inconsistency in the services provided across the studies, combining several types of intervention content was found to be more effective than a single intervention [8, 82]. Studies have shown that a combination of services improves patients’ medication adherence and glucose control. In the current study, diabetes education prevailed as the most common intervention in pharmacist-led diabetes services, with the aim of providing patients with the knowledge and skills needed to manage their clinical condition and lifestyle. Previous systematic reviews also found that diabetes education was most effective in improving diabetes control and enhancing medication adherence [8, 57, 58, 82]. During diabetes education, printed or digital materials and training or group discussions can also be considered, as they were also reported to be equally effective [8].

In the current study, medication review was the second intervention widely used during pharmacist-led diabetes management. During medication review, pharmacists optimize patients’ medications and ensure their adherence [83]. Medication review is one of the most effective tools for improving patient clinical outcomes and safety by resolving treatment complexities. Several systematic reviews have reported that medication reviews in the care of diabetic patients have improved clinical results and provided favorable economic outcomes that are not only beneficial to the self-paying patients, but also to the healthcare system [84, 85]. Other service interventions include self-care content, such as self-blood glucose monitoring and foot care; lifestyle adjustments, such as eating habits and physical exercise; drug consultation or counseling that focuses on effective use of medications; clinical intervention that includes a change in regimen or dosing adjustment that was carried out after agreement with the prescriber; and behavior-change content, such as goal-setting, cognitive behavioral therapy, and problem solving. The majority of the studies employed a variety of terminology to name their intervention techniques. This makes determining the types of specific intervention delivered challenging. A list of standardized terminologies and their meanings would be extremely valuable for practice harmonization and guaranteeing that future intervention program outcomes may be compared in a more methodical and meaningful manner.

The current study found that the duration and frequency of pharmacist-led diabetic interventions varied between the studies. A previous review found that studies with longer follow-up periods were associated with better outcomes [8]. Nevertheless, most included studies had good patient retention rates throughout the study period, which could differ in actual practice; the reason for the difference could be due to the “controlled environment” in the trial setting, in which patients were closely followed up. The same study also reported that pharmacist interventions significantly improved most of the outcome measures within three follow-up visits [8]. Hence, the delivery of content should be based on the patient’s immediate needs and should not be too structured in the view that patients may not return for their next appointment. In addition, no consistent pattern was found between intervention categories and patient outcomes. This would be difficult to identify because the majority of the included studies reported significant improvements in glucose control and medication adherence.

This study has a few limitations. Firstly, since the intended purpose of a this scoping review is to gather information on type of intervention strategies provided during pharmacist-led diabetes management, as opposed to recommending a clinical practice, quality assessment is not undertaken hence, making it impossible for any implications for practice or policy to be graded. The components of the interventions and their categorization were based on the information provided in the manuscript. Some interventions were not sufficiently explained, which may have caused limitations in the intervention categorization. However, we independently checked the assigned categories and ensured that the intervention components were identified appropriately. In addition, most included studies reported significant findings on glucose control and improvement in medication adherence, making it difficult to evaluate the effectiveness of individual intervention categories. The risk of bias assessment was not done to evaluate the study quality, as this study aimed only to provide an overview of intervention categories according to the activities described in the study.

Conclusion

Variations in intervention strategies were found in the reported studies, with the most used being diabetes education and medication review. Most studies used a combination of two or more intervention strategy categories when providing services, with no specific pattern found between the service model and patient outcomes. A standardization of terminologies used for future pharmacist-led diabetes management services should be encouraged to ensure harmonization in the service, and making it possible for more research to systematically explore the effectiveness of individual or combination of intervention strategies provided.

Availability of data and materials

All data relevant to the study are included in the article or uploaded as supplementary information.

References

  1. Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, et al. IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–81.

    Article  CAS  Google Scholar 

  2. Whiting DR, Guariguata L, Weil C, Shaw J. IDF Diabetes Atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94:311–21.

    Article  Google Scholar 

  3. Hu FB. Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes Care. 2011;34:1249–57.

    Article  Google Scholar 

  4. Liu X, Li C, Gong H, Cui Z, Fan L, Yu W, et al. An economic evaluation for prevention of diabetes mellitus in a developing country: a modelling study. BMC Public Health. 2013;13:729.

    Article  Google Scholar 

  5. Khunti K, Gray LJ, Skinner T, Carey ME, Realf K, Dallosso H, et al. Effectiveness of a diabetes education and self management programme (DESMOND) for people with newly diagnosed type 2 diabetes mellitus: three year follow-up of a cluster randomised controlled trial in primary care. BMJ. 2012;344:e2333.

    Article  Google Scholar 

  6. Azharuddin M, Adil M, Sharma M, Gyawali B. A systematic review and meta-analysis of non-adherence to anti-diabetic medication: evidence from low- and middle-income countries. Int J Clin Pract. 2021;75:e14717.

    Article  Google Scholar 

  7. Leite RGOF, Banzato LR, Galendi JSC, Mendes AL, Bolfi F, Veroniki AA, et al. Effectiveness of non-pharmacological strategies in the management of type 2 diabetes in primary care: a protocol for a systematic review and network meta-analysis. BMJ Open. 2020;10:e034481.

    Article  Google Scholar 

  8. Presley B, Groot W, Pavlova M. Pharmacy-led interventions to improve medication adherence among adults with diabetes: a systematic review and meta-analysis. Res Social Administrative Pharm. 2019;15:1057–67.

    Article  Google Scholar 

  9. You LX, Selvadurai S, Yee CK, Noh NB, Chin G, Joyce T, et al. Impact of pharmacist-managed diabetes medication therapy adherence clinic (DMTAC) in government health clinics. Malays J Pharm Sci. 2015;13:43–51.

    Google Scholar 

  10. Lim PC, Lim K, Embee ZC, Hassali MA, Thiagarajan A, Khan TM. Study investigating the impact of pharmacist involvement on the outcomes of diabetes medication therapy adherence program Malaysia. Pak J Pharm Sci. 2016;29(2):595–601.

    Google Scholar 

  11. Lau BT, Ismail SZ, Ng SY, Mohmmad N. Impact of pharmacist-led diabetes program on glycated hemoglobin and diabetes-related hospitalizations in a district-level hospital: a pilot retrospective cohort study. Int J Adv Life Sci Res. 2018;1:26–36.

    Google Scholar 

  12. Milosavljevic A, Aspden T, Harrison J. Community pharmacist-led interventions and their impact on patients’ medication adherence and other health outcomes: a systematic review. Int J Pharm Pract. 2018;26:387–97.

    Article  Google Scholar 

  13. Van Eikenhorst L, Taxis K, van Dijk L, de Gier H. Pharmacist-led self-management interventions to improve diabetes outcomes. A systematic literature review and meta-analysis. Front Pharmacol. 2017;8:891.

  14. Newman TV, San-Juan-Rodriguez A, Parekh N, Swart ECS, Klein-Fedyshin M, Shrank WH, et al. Impact of community pharmacist-led interventions in chronic disease management on clinical, utilization, and economic outcomes: an umbrella review. Res Social Administrative Pharm. 2020;16:1155–65.

    Article  Google Scholar 

  15. Peters M, Godfrey C, Mcinerney P, Soares C, Khalil H, Parker D. Methodology for JBI scoping reviews. Joanna Briggs Institute; 2015.

  16. Mahwi TO, Kawa AO. Role of the Pharmaceutical Care in the management of patients with type 2 diabetes Mellitus. Int J Pharm Sci Res. 2013;14:1363–9.

    Google Scholar 

  17. Clifford RM, Batty KT, Davis TME, Davis W, Stein G, Stewart G, et al. A randomised controlled trial of a pharmaceutical care programme in high-risk diabetic patients in an outpatient clinic. Int J Pharm Pract. 2002;10:85–9.

    Article  Google Scholar 

  18. Phumipamorn S, Pongwecharak J, Soorapan S, Pattharachayakul S. Effects of the pharmacist’s input on glycaemic control and cardiovascular risks in muslim diabetes. Prim Care Diabetes. 2008;2:31–7.

    Article  Google Scholar 

  19. Mehuys E, Van Bortel L, De Bolle L, Van Tongelen I, Annemans L, Remon J-P, et al. Effectiveness of a community pharmacist intervention in diabetes care: a randomized controlled trial: effectiveness of a pharmacist intervention in diabetes care. J Clin Pharm Ther. 2011;36:602–13.

    Article  CAS  Google Scholar 

  20. Jacobs M, Sherry PS, Taylor LM, Amato M, Tataronis GR, Cushing G. Pharmacist assisted Medication Program enhancing the regulation of diabetes (PAMPERED) study. J Am Pharmacists Association. 2012;52:613–21.

    Article  Google Scholar 

  21. Shah M, Norwood CA, Farias S, Ibrahim S, Chong PH, Fogelfeld L. Diabetes Transitional Care from Inpatient to Outpatient setting: Pharmacist Discharge Counseling. J Pharm Pract. 2013;26:120–4.

    Article  Google Scholar 

  22. Butt M, Mhd Ali A, Bakry MM, Mustafa N. Impact of a pharmacist led diabetes mellitus intervention on HbA1c, medication adherence and quality of life: a randomised controlled study. Saudi Pharm J. 2016;24:40–8.

    Article  Google Scholar 

  23. Samtia A, Rasool M, Ranjha N, Usman F, Javed I. A multifactorial intervention to Enhance Adherence to Medications and Disease-Related knowledge in type 2 Diabetic patients in Southern Punjab, Pakistan. Trop J Pharm Res. 2013;12:851–6.

    Google Scholar 

  24. Doucette WR, Witry MJ, Farris KB, Mcdonough RP. Community pharmacist–provided extended Diabetes Care. Ann Pharmacother. 2009;43:882–9.

    Article  Google Scholar 

  25. Jaber LA, Halapy H, Fernet M, Tummalapalli S, Diwakaran H. Evaluation of a Pharmaceutical Care Model on Diabetes Management. Ann Pharmacother. 1996;30:238–43.

    Article  CAS  Google Scholar 

  26. Kraemer DF, Kradjan WA, Bianco TM, Low JA. A randomized study to assess the impact of Pharmacist Counseling of Employer-Based Health Plan beneficiaries with diabetes: the EMPOWER Study. J Pharm Pract. 2012;25:169–79.

    Article  Google Scholar 

  27. Mourão AOM, Ferreira WR, Martins MAP, Reis AMM, Carrillo MRG, Guimarães AG, et al. Pharmaceutical care program for type 2 diabetes patients in Brazil: a randomised controlled trial. Int J Clin Pharm. 2013;35:79–86.

    Article  Google Scholar 

  28. Kirwin JL, Cunningham RJ, Sequist TD. Pharmacist recommendations to improve the quality of Diabetes Care: a Randomized Controlled Trial. JMCP. 2010;16:104–13.

    Article  Google Scholar 

  29. Javaid Z, Imtiaz U, Khalid I, Saeed H, Khan RQ, Islam M, et al. A randomized control trial of primary care-based management of type 2 diabetes by a pharmacist in Pakistan. BMC Health Serv Res. 2019;19:409.

    Article  Google Scholar 

  30. Ayadurai S, Sunderland VB, Tee LBG, Md Said SN, Hattingh HL. Structured tool to improve clinical outcomes of type 2 diabetes mellitus patients: a randomized controlled trial. J Diabetes. 2018;10:965–76.

    Article  CAS  Google Scholar 

  31. Taveira TH, Friedmann PD, Cohen LB, Dooley AG, Khatana SAM, Pirraglia PA, et al. Pharmacist-led Group Medical Appointment Model in Type 2 diabetes. Diabetes Educ. 2010;36:109–17.

    Article  Google Scholar 

  32. Wu W-C, Taveira TH, Jeffery S, Jiang L, Tokuda L, Musial J, et al. Costs and effectiveness of pharmacist-led group medical visits for type-2 diabetes: a multi-center randomized controlled trial. PLoS ONE. 2018;13:e0195898.

    Article  Google Scholar 

  33. Withidpanyawong U, Lerkiatbundit S, Saengcharoen W. Family-based intervention by pharmacists for type 2 diabetes: a randomised controlled trial. Patient Educ Couns. 2019;102:85–92.

    Article  Google Scholar 

  34. Sarayani A, Mashayekhi M, Nosrati M, Jahangard-Rafsanjani Z, Javadi M, Saadat N, et al. Efficacy of a telephone-based intervention among patients with type-2 diabetes; a randomized controlled trial in pharmacy practice. Int J Clin Pharm. 2018;40:345–53.

    Article  Google Scholar 

  35. Xin C, Xia Z, Jiang C, Lin M, Li G. Effect of pharmaceutical care on medication adherence of patients newly prescribed insulin therapy: a randomized controlled study. PPA. 2015;102:797.

    Article  Google Scholar 

  36. Chen J-H, Ou H-T, Lin T-C, Lai EC-C, Yang Kao Y-H. Pharmaceutical care of elderly patients with poorly controlled type 2 diabetes mellitus: a randomized controlled trial. Int J Clin Pharm. 2016;38:88–95.

    Article  CAS  Google Scholar 

  37. Scott DM, Boyd ST, Stephan M, Augustine SC, Reardon TP. Outcomes of pharmacist-managed diabetes care services in a community health center. Am J Health-System Pharm. 2006;63:2116–22.

    Article  Google Scholar 

  38. Clifford RM, Davis WA, Batty KT, Davis TME. Effect of a Pharmaceutical Care Program on vascular risk factors in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care. 2005;28:771–6.

    Article  Google Scholar 

  39. Plaster CP, Melo DT, Boldt V, et al. Reduction of cardiovascular risk in patients with metabolic syndrome in a community health center after a pharmaceutical care program of pharmacotherapy follow-up. Braz J Pharm Sci. 2012;48:435–46.

    Article  Google Scholar 

  40. Odegard PS, Goo A, Hummel J, Williams KL, Gray SL. Caring for poorly controlled diabetes mellitus: a randomized pharmacist intervention. Ann Pharmacother. 2005;39:433–40.

    Article  Google Scholar 

  41. Chan C-W, Siu S-C, Wong CKW, Lee VWY. A Pharmacist Care Program: positive impact on Cardiac risk in patients with type 2 diabetes. J Cardiovasc Pharmacol Ther. 2012;17:57–64.

    Article  Google Scholar 

  42. Choe HM, Mitrovich S, Dubay D, Hayward RA, Krein SL, Vijan S. Proactive Case Management of High-risk patients with type 2 diabetes Mellitus by a clinical pharmacist: a Randomized Controlled Trial. Am J Manag Care. 2005;11:8.

    Google Scholar 

  43. Rothman RL, Malone R, Bryant B, Shintani AK, Crigler B, Dewalt DA, et al. A randomized trial of a primary care-based disease management program to improve cardiovascular risk factors and glycated hemoglobin levels in patients with diabetes. Am J Med. 2005;118:276–84.

    Article  Google Scholar 

  44. Erku D, Belachew S, Tegegn H, Ayele A. The impact of Pharmacist-LED medication Therapy Management on Medication Adherence in patients with type 2 diabetes Mellitus: a randomized controlled study. Value in Health. 2017;20:A402.

    Article  Google Scholar 

  45. Ojieabu W, Bello S, Arute J. Evaluation of pharmacists’ educational and counselling impact on patients’ clinical outcomes in a diabetic setting. J Diabetol. 2017;8:7.

    Article  Google Scholar 

  46. Shao H, Chen G, Zhu C, Chen Y, Liu Y, He Y, et al. Effect of pharmaceutical care on clinical outcomes of outpatients with type 2 diabetes mellitus. PPA. 2017;11:897–903.

    Article  Google Scholar 

  47. Jameson JP, Baty PJ. Pharmacist collaborative management of poorly controlled diabetes mellitus: a randomized controlled trial. Am J Manag Care. 2010;16:250–5.

    Google Scholar 

  48. Odegard PS, Christensen DB. MAP study: RCT of a medication adherence program for patients with type 2 diabetes. J Am Pharmacists Association. 2012;52:753–62.

    Article  Google Scholar 

  49. Jarab AS, Alqudah SG, Mukattash TL, Shattat G, Al-Qirim T. Randomized Controlled Trial of Clinical Pharmacy Management of patients with type 2 diabetes in an Outpatient Diabetes Clinic in Jordan. JMCP. 2012;18:516–26.

    Article  Google Scholar 

  50. Wishah RA, Al-Khawaldeh OA, Albsoul AM. Impact of pharmaceutical care interventions on glycemic control and other health-related clinical outcomes in patients with type 2 diabetes: randomized controlled trial. Diabetes Metab Syndr. 2015;9:271–6.

    Article  Google Scholar 

  51. Chung WW, Chua SS, Lai PS, Chan SP. Effects of a pharmaceutical care model on medication adherence and glycemic control of people with type 2 diabetes. Patient Prefer Adherence. 2014;8:1185–94.

    Google Scholar 

  52. Abuloha S, Alabbadi I, Albsoul-Younes A, Younes N, Zayed A. The role of clinical pharmacist in initiation and/or Dose Adjustment of insulin therapy in Diabetic Patients in Outpatient Clinic in Jordan. Jordan J Pharm Sci. 2016;9:18.

    Article  Google Scholar 

  53. Jahangard-Rafsanjani Z, Sarayani A, Nosrati M, Saadat N, Rashidian A, Hadjibabaie M, et al. Effect of a community pharmacist–delivered diabetes support program for patients receiving Specialty Medical Care: a Randomized Controlled Trial. Diabetes Educ. 2015;41:127–35.

    Article  Google Scholar 

  54. Aguiar PM, Silva CHP, Chiann C, Dórea EL, Lyra DP, Storpirtis S. Pharmacist–physician collaborative care model for patients with uncontrolled type 2 diabetes in Brazil: results from a randomized controlled trial. J Eval Clin Pract. 2018;24:22–30.

    Article  Google Scholar 

  55. Sriram S, Chack LE, Ramasamy R, Ghasemi A, Ravi TK, Sabzghabaee AM. Impact of pharmaceutical care on quality of life in patients with type 2 diabetes mellitus. J Res Med Sci. 2011;16:412–8.

    Google Scholar 

  56. Farsaei S, Sabzghabaee AM, Zargarzadeh AH, Amini M. Effect of pharmacist-led patient education on glycemic control of type 2 diabetics: a randomized controlled trial. J Res Med Sci. 2011;16:43–9.

    Google Scholar 

  57. Omran D, Guirguis LM, Simpson SH. Systematic review of Pharmacist Interventions to improve adherence to oral antidiabetic medications in people with type 2 diabetes. Can J Diabetes. 2012;36:292–9.

    Article  Google Scholar 

  58. Pousinho S, Morgado M, Falcão A, Alves G. Pharmacist interventions in the management of type 2 diabetes Mellitus: a systematic review of Randomized controlled trials. JMCP. 2016;22:493–515.

    Article  Google Scholar 

  59. Ramanath K, Balaji D, Nagakishore C, Kumar SM, Bhanuprakash M. A study on impact of clinical pharmacist interventions on medication adherence and quality of life in rural hypertensive patients. J Young Pharm. 2012;4:95–100.

    Article  Google Scholar 

  60. Renuga E, Ramakrishnan SR, Rani N, Palani T, Kannan G. Impact of continuous patient counselling on knowledge, attitude, and practices and medication adherence of diabetic patients attending outpatient pharmacy services. Asian J Pharm Clin Res. 2016;9:345–50.

    Google Scholar 

  61. Grant RW, Devita NG, Singer DE, Meigs JB. Polypharmacy and medication adherence in patients with type 2 diabetes. Diabetes Care. 2003;26:1408–12.

    Article  Google Scholar 

  62. Lyons I, Barber N, Raynor DK, Wei L. The Medicines advice service evaluation (MASE): a randomised controlled trial of a pharmacist-led telephone based intervention designed to improve medication adherence. BMJ Qual Saf. 2016;25:759–69.

    Article  Google Scholar 

  63. Fornos JA, Andrés NF, Andrés JC, Guerra MM, Egea B. A Pharmacotherapy Follow-Up program in patients with Type-2 diabetes in Community Pharmacies in Spain. Pharm World Sci. 2006;28:65–72.

    Article  Google Scholar 

  64. Malathy R, Narmadha MP, Alvin Jose M, Ramesh S, Dinesh Babu N. Effect of a diabetes Counseling Programme on Knowledge, attitude and practice among Diabetic Patients in Erode District of South India. J Young Pharmacists. 2011;3:65–72.

    Article  CAS  Google Scholar 

  65. Lauffenburger JC, Lewey J, Jan S, Makanji S, Ferro CA, Krumme AA, et al. Effectiveness of targeted insulin-adherence interventions for Glycemic Control using Predictive Analytics among patients with type 2 diabetes: a Randomized Clinical Trial. JAMA Netw Open. 2019;2:e190657.

    Article  Google Scholar 

  66. Michiels Y, Bugnon O, Chicoye A, Dejager S, Moisan C, Allaert FA, et al. Impact of a community pharmacist-delivered information program on the follow-up of type-2 diabetic patients: a cluster randomized controlled study. Adv Ther. 2019;36:1291–303.

    Article  CAS  Google Scholar 

  67. Ghosh S, Rajvanshi AK, Kishun S. Assessment the influence of patient counseling on uqality of life in type-II diabetes mellitus patients. Int J Pharma Bio Sci. 2010;1:1–6.

    Google Scholar 

  68. Nagavi B, Adepu R, Rasheed A. Effect of patient counseling on quality of life in type-2 diabetes mellitus patients in two selected south indian community pharmacies: a study. Indian J Pharm Sci. 2007;69:519.

    Article  Google Scholar 

  69. Al Mazroui NR, Kamal MM, Ghabash NM, Yacout TA, Kole PL, McElnay JC. Influence of pharmaceutical care on health outcomes in patients with type 2 diabetes mellitus. Br J Clin Pharmacol. 2009;67:547–57.

    Article  CAS  Google Scholar 

  70. Chow EP, Hassali MA, Saleem F, Aljadhey H. Effects of pharmacist-led patient education on diabetes-related knowledge and medication adherence: a home-based study. Health Educ J. 2016;75:421–33.

    Article  Google Scholar 

  71. Sarkadi A, Rosenqvist U. Experience-based group education in type 2 diabetes. Patient Educ Couns. 2004;53:291–8.

    Article  Google Scholar 

  72. Venkatesan R, Manjula Devi A, Parasuraman S, Sriram S. Role of community pharmacists in improving knowledge and glycemic control of type 2 diabetes. Perspect Clin Res. 2012;3:26.

    Article  CAS  Google Scholar 

  73. Cohen LB, Taveira TH, Khatana SAM, Dooley AG, Pirraglia PA, Wu W-C. Pharmacist-led Shared Medical appointments for multiple Cardiovascular Risk reduction in patients with type 2 diabetes. Diabetes Educ. 2011;37:801–12.

    Article  Google Scholar 

  74. Castejón AM, Calderón JL, Perez A, Millar C, McLaughlin-Middlekauff J, Sangasubana N, et al. A community-based pilot study of a diabetes pharmacist intervention in Latinos: Impact on Weight and Hemoglobin A1c. J Health Care Poor Underserved. 2014;24:48–60.

    Article  Google Scholar 

  75. Cani C, Lopes L, Queiroz M, Nery M. Improvement in medication adherence and self-management of diabetes with a clinical pharmacy program: a randomized controlled trial in patients with type 2 diabetes undergoing insulin therapy at a teaching hospital. Clinics. 2015;70:102–6.

    Article  Google Scholar 

  76. Korcegez EI, Sancar M, Demirkan K. Effect of a pharmacist-led program on improving outcomes in patients with type 2 diabetes Mellitus from Northern Cyprus: a Randomized Controlled Trial. JMCP. 2017;23:573–82.

    Article  Google Scholar 

  77. Ali M, Schifano F, Robinson P, Phillips G, Doherty L, Melnick P, et al. Impact of community pharmacy diabetes monitoring and education programme on diabetes management: a randomized controlled study: community pharmacy diabetes monitoring and education programme. Diabet Med. 2012;29:e326–33.

    Article  CAS  Google Scholar 

  78. Ruiz-Ramos J, Hernández MH, Juanes-Borrego AM, Milà R, Mangues-Bafalluy MA, Mestres C. The impact of Pharmaceutical Care in Multidisciplinary Teams on Health Outcomes: systematic review and Meta-analysis. J Am Med Dir Assoc. 2021;22:2518–26.

    Article  Google Scholar 

  79. Howarth E, Bower PJ, Kontopantelis E, Soiland-Reyes C, Meacock R, Whittaker W, et al. ‘Going the distance’: an independent cohort study of engagement and dropout among the first 100 000 referrals into a large-scale diabetes prevention program. BMJ Open Diabetes Research and Care. 2020;8:e001835.

    Article  Google Scholar 

  80. Cao DX, Tran RJC, Yamzon J, Stewart TL, Hernandez EA. Effectiveness of telepharmacy diabetes services: a systematic review and meta-analysis. Am J Health Syst Pharm. 2022;79:860–72.

    Article  Google Scholar 

  81. Behavioural Interventions for Type 2 Diabetes. Ont Health Technol Assess Ser. 2009;9:1–45.

    Google Scholar 

  82. Sapkota S, Brien J, Greenfield J, Aslani P. A systematic review of interventions addressing adherence to anti-diabetic medications in patients with type 2 diabetes–impact on adherence. PLoS ONE. 2015;10:e0118296.

    Article  Google Scholar 

  83. Geurts MME, Talsma J, Brouwers JRBJ, de Gier JJ. Medication review and reconciliation with cooperation between pharmacist and general practitioner and the benefit for the patient: a systematic review. Br J Clin Pharmacol. 2012;74:16–33.

    Article  Google Scholar 

  84. Jokanovic N, Tan ECK, van den Bosch D, Kirkpatrick CM, Dooley MJ, Bell JS. Clinical medication review in Australia: a systematic review. Res Social Administrative Pharm. 2016;12:384–418.

    Article  Google Scholar 

  85. Ahumada-Canale A, Quirland C, Martinez-Mardones FJ, Plaza-Plaza JC, Benrimoj S, Garcia-Cardenas V. Economic evaluations of pharmacist-led medication review in outpatients with hypertension, type 2 diabetes mellitus, and dyslipidaemia: a systematic review. Eur J Health Econ. 2019;20:1103–16.

    Article  Google Scholar 

Download references

Acknowledgements

We would like to thank the Quality Management of Medicines Research Group, Faculty of Pharmacy, Universiti Kebangsaan Malaysia for providing support for this study. We would also like to thank Ministry of Health Malaysia and Public Services Division Malaysia for awarding study scholarship (Hadiah Latihan Persekutuan) for FH.

Funding

This study received funding from the Research University Grant of Universiti Kebangsaan Malaysia reference number GUP-2021-010.

Author information

Authors and Affiliations

  1. Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 50300, Kuala Lumpur, Malaysia

    Fahmi Hassan, Ernieda Hatah, Adliah Mhd Ali & Chong Wei Wen

  2. Pharmacy Services Program, Ministry of Health Malaysia, Lot 36 Jalan Universiti, 46350, Petaling Jaya, Selangor, Malaysia

    Fahmi Hassan

Authors
  1. Fahmi Hassan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ernieda Hatah
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Adliah Mhd Ali
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chong Wei Wen
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

This study was conceived by F.H. and E.H. F.H. and E.H. conducted the searches, appraisal, extraction and analysis with input from A.M.A and C.W.W. All authors contributed to writing the draft manuscript and approved the final version.

Corresponding author

Correspondence to Ernieda Hatah.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hassan, F., Hatah, E., Ali, A.M. et al. The intervention strategies and service model for pharmacist-led diabetes management: a scoping review. BMC Health Serv Res 23, 46 (2023). https://doi.org/10.1186/s12913-022-08977-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12913-022-08977-1

Keywords

  • Diabetes
  • Pharmacist
  • Non-pharmacological interventions
  • Patient management

BMC Health Services Research

ISSN: 1472-6963

Contact us